Market-leading retailer with 35.2% ROIC trading at fair value $67.02, facing e-commerce disruption whilst maintaining exceptional operational efficiency and 25% market share.
View noteSpeculative transformation play trading at 76% discount to $0.74 fair value. Strong balance sheet ($40.6m net cash) provides runway but execution risk substantial with 30% management track record.
View noteHOLD rating with $6.03 fair value vs $7.96 current price. Strong business quality (8.04/10) but overvalued with 24% downside risk despite transformation success.
View noteRevolutionary HAMR technology targets 75% cost reduction in $7B titanium market. Fair value $0.95 vs current $0.35 implies 171% upside potential.
View noteIPH trades at $4.78 vs fair value $9.29 (94% upside). Market leader with 29.3% Australian share, CIPO recovery catalyst, 32% EBITDA margin target.
View noteHOLD rating with $3.28 fair value vs $3.73 current price. Revenue growth moderating to 5.7% CAGR with margin compression pressures.
View noteHOLD rating with $3.60 fair value vs $5.96 current price. Strong demographics offset by execution risks and regulatory headwinds.
View noteFair value $0.30 vs current $1.37 implies 78% downside risk. Monopolistic MRI-compatible cardiac ablation technology with FDA approval catalyst, but extreme 195x revenue valuation creates unfavourable risk-reward profile.
View noteMining technology leader trading at 44% premium to $2.36 fair value. Strong 29.3% EBITDA margins, 490+ patents, but execution risks from three simultaneous acquisitions amid uncertain exploration recovery.
View noteIVE Group trades at $2.99 vs fair value $8.19, offering 174% upside through portfolio transformation from print to packaging/logistics. Market leader with strong execution track record.
View noteAustralia's #2 diagnostic imaging provider trading at 129% premium to $1.16 fair value. High leverage, workforce constraints, and technology disruption create asymmetric downside risk.
View noteClinical-stage biotechnology company trading at $1.62 vs fair value $0.13, facing 65% Phase 2 failure probability with extreme dilution risk ahead.
View note